PMS18 COSTS OF TREATMENT OF RHEUMATOID ARTHRITIS WITH BIOLOGICAL DRUGS

Bone mineral density changes during treatment of rheumatoid arthritis with disease-modifying-anti-rheumatic drugs

Background: Bone mineral density (BMD) changes during the course of rheumatoid arthritis (RA). The present study was designed to investigate the status of BMD in patients with RA treated with anti-rheumatic drugs. Methods: BMD at the femoral neck (FN-BMD) and lumbar spine (LS-BMD) were measured by dual energy x-ray absorptiometry (DXA) method using Norland densitometer. Disease activity (DA) wa...

Treatment of Rheumatoid Arthritis with Biological Agents

Cytokines and Rheumatoid Arthritis The term “cytokine” is coined from the combination of “cyto”, a prefix which means cell, and “kine”, which denotes movement. Cytokines all have the following features: 1. They are low-molecular-weight glycoproteins that are not hormones. 2. They have an effect at very small concentrations. 3. Different cytokines can have the same function (redundancy). For exa...

second patient with seronegative rheumatoid arthritis and treatment with diet

second patient with seronegative rheumatoid arthritis and treatment with diet

Administration costs of intravenous biologic drugs for rheumatoid arthritis

BACKGROUND Cost-effectiveness studies explicitly reporting infusion times, drug-specific administration costs for infusions or real-payer intravenous drug cost are few in number. Yet, administration costs for infusions are needed in the health economic evaluations assessing intravenously-administered drugs. OBJECTIVES To estimate the drug-specific administration and total cost of biologic int...

Treatment of rheumatoid arthritis and other inflammatory disorders with biological drugs